New cancer pill AN4005 enters first human tests
NCT ID NCT04999384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new experimental drug called AN4005 in about 31 people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants take the drug by mouth twice a day at different dose levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150081, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Einstein Cancer Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prisma Health Institute for Translational Oncology Research
RECRUITINGGreenville, South Carolina, 29605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AN4005 (an experimental drug taken as a pill)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors or lymphoma who have run out of standard therapies.
What could go wrong
This is a very early, first-in-human study with only 31 participants. The drug may not be safe or effective at higher doses, and side effects are unknown. Many early-stage cancer drugs never advance.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.